197 related articles for article (PubMed ID: 7538001)
1. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
[TBL] [Abstract][Full Text] [Related]
2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
3. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Schulze E; Krahl R; Thalmeier K; Helbig W
Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Maki G; Tam YK; Berkahn L; Klingemann HG
Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
[TBL] [Abstract][Full Text] [Related]
6. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
7. [Study on T lymphocyte recognition of tumor antigens on autologous CML cells].
Chen Y; Hao Y; You S; Wei D; Wei D; Liao X; Ding S; Liu S; Wei D
Zhonghua Xue Ye Xue Za Zhi; 1997 Dec; 18(12):638-41. PubMed ID: 15625763
[TBL] [Abstract][Full Text] [Related]
8. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
10. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
11. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia.
Jiang YZ; Barrett AJ
Exp Hematol; 1995 Oct; 23(11):1167-72. PubMed ID: 7556526
[TBL] [Abstract][Full Text] [Related]
12. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
Cervantes F; Miller JS; McGlave PB
Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
Verma UN; Bagg A; Brown E; Mazumder A
Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
[TBL] [Abstract][Full Text] [Related]
14. Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Hows JM; Goldman JM
Leukemia; 1990 Apr; 4(4):287-91. PubMed ID: 2366584
[TBL] [Abstract][Full Text] [Related]
15. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
[TBL] [Abstract][Full Text] [Related]
16. Potential of autologous immunologic effector cells for prediction of progression of disease in patients with chronic myelogenous leukemia.
Müller M; Scheffold C; Lefterova P; Huhn D; Neubauer A; Schmidt-Wolf IG
Leuk Lymphoma; 1998 Oct; 31(3-4):335-41. PubMed ID: 9869197
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
Long GS; Cramer DV; Harnaha JB; Hiserodt JC
Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
[TBL] [Abstract][Full Text] [Related]
18. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
Huang H; Chen Y; Chen W; Wu Y
Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
[TBL] [Abstract][Full Text] [Related]
19. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells.
Lewalle P; Hensel N; Guimaraes A; Couriel D; Jiang Y Z; Mavroudis D; Barrett AJ
Br J Haematol; 1996 Mar; 92(3):587-94. PubMed ID: 8616022
[TBL] [Abstract][Full Text] [Related]
20. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
